1. Cognitive impairment in adolescent and young adult cancer patients: Pre‐treatment findings of a longitudinal study
- Author
-
Chan, Alexandre, Cheng, Ivy, Wang, Claire, Tan, Chia Jie, Toh, Yi Long, Ng, Ding Quan, Koh, Yong Qin, Zhou, Hanzhang, Foo, Koon Mian, Chan, Raymond Javan, Ho, Han Kiat, Chew, Lita, Farid, Mohamad, and Tannock, Ian
- Subjects
Paediatrics ,Biomedical and Clinical Sciences ,Neurosciences ,Clinical Research ,Pediatric ,Rare Diseases ,Behavioral and Social Science ,Cancer ,Humans ,Young Adult ,Adolescent ,Adult ,Brain-Derived Neurotrophic Factor ,Longitudinal Studies ,Quality of Life ,Cohort Studies ,Cognitive Dysfunction ,Neoplasms ,adolescent and young adult ,brain-derived neurotrophic factor ,cancer ,cancer-related cognitive impairment ,cognition ,inflammatory cytokines ,Biochemistry and Cell Biology ,Oncology and Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundThere is little information about cancer-related cognitive impairment (CRCI) in adolescent and young adults (AYA, 15-39 years old) due to its rare incidence. Here, we present the pre-treatment (before chemotherapy or radiotherapy) evaluation of cognitive function and ability of AYA with cancer (AYAC) in a multicentered cohort study.MethodsNewly diagnosed AYAC and age-matched healthy controls (HC) were recruited between 2018 and 2021. The primary outcome was the comparison of pre-treatment cognitive impairment defined as 2 standard deviations (SDs) below the HC on ≥1 cognitive test, or >1.5 SDs below on ≥2 tests using CANTAB® between AYAC and HC. Secondary outcomes included self-perceived cognitive ability assessed by FACT-Cog v3 and biomarkers (inflammatory cytokines and brain-derived neurotrophic factor [BDNF]).ResultsWe recruited 74 AYAC (median age = 34) and 118 HC (median age = 32). On objective cognitive testing, we observed three times more AYAC patients performed poorly on at least 2 cognitive tests compared to HC (40.5% vs. 13.6%, p
- Published
- 2023